CN102137866A - 羟吲哚化合物 - Google Patents

羟吲哚化合物 Download PDF

Info

Publication number
CN102137866A
CN102137866A CN2009801336712A CN200980133671A CN102137866A CN 102137866 A CN102137866 A CN 102137866A CN 2009801336712 A CN2009801336712 A CN 2009801336712A CN 200980133671 A CN200980133671 A CN 200980133671A CN 102137866 A CN102137866 A CN 102137866A
Authority
CN
China
Prior art keywords
compound
alkyl
substituted
nrz
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801336712A
Other languages
English (en)
Chinese (zh)
Inventor
穆斯塔法.哈达科
J·Y·纳盖萨瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cylene Pharmaceuticals Inc
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of CN102137866A publication Critical patent/CN102137866A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801336712A 2008-06-30 2009-06-30 羟吲哚化合物 Pending CN102137866A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7709108P 2008-06-30 2008-06-30
US61/077,091 2008-06-30
US15642609P 2009-02-27 2009-02-27
US61/156,426 2009-02-27
US18009509P 2009-05-20 2009-05-20
US61/180,095 2009-05-20
PCT/US2009/049318 WO2010002933A1 (en) 2008-06-30 2009-06-30 Oxindole compounds

Publications (1)

Publication Number Publication Date
CN102137866A true CN102137866A (zh) 2011-07-27

Family

ID=41466309

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801336712A Pending CN102137866A (zh) 2008-06-30 2009-06-30 羟吲哚化合物

Country Status (12)

Country Link
US (2) US8124649B2 (https=)
EP (1) EP2307421A4 (https=)
JP (1) JP2011526917A (https=)
KR (1) KR20110025996A (https=)
CN (1) CN102137866A (https=)
AU (1) AU2009267048A1 (https=)
BR (1) BRPI0914942A2 (https=)
CA (1) CA2729745A1 (https=)
IL (1) IL210355A0 (https=)
MX (1) MX2011000150A (https=)
WO (1) WO2010002933A1 (https=)
ZA (1) ZA201100539B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103509009A (zh) * 2012-06-21 2014-01-15 中国科学院上海药物研究所 2-取代-5-苯基呋喃类化合物、其制备方法、药物组合物及其用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2819373A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
CN102688234B (zh) * 2011-03-21 2015-07-29 华东理工大学 吲哚酮衍生物作为rsk2抑制剂的合成与应用
JP2014510105A (ja) 2011-03-22 2014-04-24 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としてのアゾール化合物
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
PL3303330T3 (pl) 2015-06-03 2019-10-31 Bristol Myers Squibb Co Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3187496A1 (de) 2015-12-30 2017-07-05 Heliatek GmbH Verbindung für fotoaktive organische elektronische bauelemente und fotoaktives organisches elektronisches bauelement enthaltend die verbindung
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
WO2025085819A1 (en) * 2023-10-18 2025-04-24 Washington University Kinase inhibitor compositions and related methods for the treatment of a disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096361A2 (en) * 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
CN1898205A (zh) * 2003-10-24 2007-01-17 舍林股份公司 吲哚满酮衍生物及其在治疗疾病状态如癌症中的用途
JP2007084494A (ja) * 2005-09-22 2007-04-05 Oncorex Inc Ｐｉｍ−１活性阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US20030119895A1 (en) * 1998-12-23 2003-06-26 Pharmacia Corporation Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
JP3663382B2 (ja) * 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US8367664B2 (en) * 2006-01-24 2013-02-05 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
WO2007087429A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
DK1973910T3 (da) 2006-01-27 2013-08-12 Shanghai Hengrui Pharm Co Ltd Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
WO2002096361A2 (en) * 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
CN1898205A (zh) * 2003-10-24 2007-01-17 舍林股份公司 吲哚满酮衍生物及其在治疗疾病状态如癌症中的用途
JP2007084494A (ja) * 2005-09-22 2007-04-05 Oncorex Inc Ｐｉｍ−１活性阻害剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABDULHAMEED，等: "Combined 3D-QSAR Modeling and Molecular Docking Study on Indolinone Derivatives as Inhibitors of 3-Phosphoinositide-Dependent Protein Kinase-1", 《J. CHEM. INF. MODEL.》 *
IMADUL ISLAM，等: "Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
TAO JIANG,等: "Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
XIAO-CHEN YAN，等: "1-Acetyl-3,3-bis[3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-ylmethyl]indolin-2-one", 《ACTA CRYSTALLOGRAPHICA SECTION E》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103509009A (zh) * 2012-06-21 2014-01-15 中国科学院上海药物研究所 2-取代-5-苯基呋喃类化合物、其制备方法、药物组合物及其用途

Also Published As

Publication number Publication date
IL210355A0 (en) 2011-03-31
MX2011000150A (es) 2011-04-05
CA2729745A1 (en) 2010-01-07
EP2307421A4 (en) 2011-07-13
US20100041635A1 (en) 2010-02-18
WO2010002933A1 (en) 2010-01-07
KR20110025996A (ko) 2011-03-14
JP2011526917A (ja) 2011-10-20
US20120190669A1 (en) 2012-07-26
ZA201100539B (en) 2011-11-30
US8124649B2 (en) 2012-02-28
AU2009267048A1 (en) 2010-01-07
EP2307421A1 (en) 2011-04-13
BRPI0914942A2 (pt) 2015-08-11

Similar Documents

Publication Publication Date Title
CN102137866A (zh) 羟吲哚化合物
CN104370828B (zh) 用作raf激酶抑制剂的嘧啶衍生物
JP6047556B2 (ja) Ｌｒｒｋ２キナーゼ活性の阻害剤
US20100331315A1 (en) Rhodanines and related heterocycles as kinase inhibitors
JP2008534664A (ja) 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
WO2018045956A1 (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
JP2015187181A (ja) Ｉｄｏ阻害剤
WO2018010514A1 (zh) 作为fgfr抑制剂的杂环化合物
WO2017080338A1 (zh) 丙烯酸类衍生物、其制备方法及其在医药上的用途
KR20070107104A (ko) Ｒａｆ 억제제 화합물 및 방법
JP2010514676A (ja) タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
CN104812756A (zh) 多激酶通路抑制剂
TW200829589A (en) Compound for inhibiting mitotic progression
BR122023004130B1 (pt) Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1
JP2009538309A (ja) プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
WO2018001232A1 (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
JP2023530733A (ja) 免疫抑制剤、その製造方法及び応用
JP2012524076A (ja) プロテインキナーゼｃｋ２活性に関連する障害の治療方法
CN102770426A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN107074843A (zh) 杂芳族化合物及其作为多巴胺d1配体的用途
CN113518779B (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
TW202320750A (zh) 含四氫呋喃多環類衍生物、其藥學上可接受的鹽及其製備方法和應用
JP2010510216A (ja) プロテインキナーゼのインヒビターとして有用な化合物
CA2946990A1 (en) Heterocyclic compounds and their use as dopamine d1 ligands
CN101189243A (zh) 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110727